文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

何时应使用析因设计进行后期随机对照试验?

When should factorial designs be used for late-phase randomised controlled trials?

机构信息

MRC Clinical Trials Unit at UCL, London, UK.

出版信息

Clin Trials. 2024 Apr;21(2):162-170. doi: 10.1177/17407745231206261. Epub 2023 Oct 31.


DOI:10.1177/17407745231206261
PMID:37904490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7615816/
Abstract

BACKGROUND: A 2×2 factorial design evaluates two interventions (A versus control and B versus control) by randomising to control, A-only, B-only or both A and B together. Extended factorial designs are also possible (e.g. 3×3 or 2×2×2). Factorial designs often require fewer resources and participants than alternative randomised controlled trials, but they are not widely used. We identified several issues that investigators considering this design need to address, before they use it in a late-phase setting. METHODS: We surveyed journal articles published in 2000-2022 relating to designing factorial randomised controlled trials. We identified issues to consider based on these and our personal experiences. RESULTS: We identified clinical, practical, statistical and external issues that make factorial randomised controlled trials more desirable. Clinical issues are (1) interventions can be easily co-administered; (2) risk of safety issues from co-administration above individual risks of the separate interventions is low; (3) safety or efficacy data are wanted on the combination intervention; (4) potential for interaction (e.g. effect of A differing when B administered) is low; (5) it is important to compare interventions with other interventions balanced, rather than allowing randomised interventions to affect the choice of other interventions; (6) eligibility criteria for different interventions are similar. Practical issues are (7) recruitment is not harmed by testing many interventions; (8) each intervention and associated toxicities is unlikely to reduce either adherence to the other intervention or overall follow-up; (9) blinding is easy to implement or not required. Statistical issues are (10) a suitable scale of analysis can be identified; (11) adjustment for multiplicity is not required; (12) early stopping for efficacy or lack of benefit can be done effectively. External issues are (13) adequate funding is available and (14) the trial is not intended for licensing purposes. An overarching issue (15) is that factorial design should give a lower sample size requirement than alternative designs. Across designs with varying non-adherence, retention, intervention effects and interaction effects, 2×2 factorial designs require lower sample size than a three-arm alternative when one intervention effect is reduced by no more than 24%-48% in the presence of the other intervention compared with in the absence of the other intervention. CONCLUSIONS: Factorial designs are not widely used and should be considered more often using our issues to consider. Low potential for at most small to modest interaction is key, for example, where the interventions have different mechanisms of action or target different aspects of the disease being studied.

摘要

背景:2×2 析因设计通过随机分配至对照组、仅 A 组、仅 B 组或 A 和 B 联合组来评估两种干预措施(A 与对照和 B 与对照)。扩展析因设计也是可能的(例如 3×3 或 2×2×2)。析因设计通常比替代的随机对照试验需要更少的资源和参与者,但它们并未广泛使用。在将其用于后期阶段之前,我们确定了考虑这种设计的研究人员需要解决的几个问题。

方法:我们调查了 2000 年至 2022 年发表的与设计析因随机对照试验相关的期刊文章。我们根据这些文章和我们的个人经验确定了需要考虑的问题。

结果:我们确定了使析因随机对照试验更可取的临床、实际、统计和外部问题。临床问题是(1)干预措施可以容易地共同给予;(2)共同给予的安全性问题的风险低于单独干预措施的个别风险较低;(3)需要关于联合干预措施的安全性或疗效数据;(4)相互作用的可能性(例如,给予 B 时 A 的作用不同)较低;(5)比较与其他干预措施平衡的干预措施而不是允许随机干预措施影响其他干预措施的选择很重要;(6)不同干预措施的纳入标准相似。实际问题是(7)测试许多干预措施不会损害招募;(8)每种干预措施及其相关毒性不太可能降低对另一种干预措施的依从性或整体随访;(9)容易实施或不需要盲法。统计问题是(10)可以确定合适的分析尺度;(11)不需要调整多重性;(12)可以有效地进行疗效或缺乏益处的早期停止。外部问题是(13)有足够的资金可用,(14)试验不是为了许可目的。一个总体问题(15)是析因设计应比替代设计要求更低的样本量要求。在具有不同不依从性、保留率、干预效果和相互作用效果的设计中,当与不存在另一种干预措施相比,一种干预措施的效果降低不超过 24%-48%时,2×2 析因设计比三臂替代设计需要更低的样本量。

结论:析因设计并未广泛使用,应根据我们确定的问题更多地考虑使用。最大小到适度相互作用的潜力低是关键,例如,干预措施具有不同的作用机制或针对正在研究的疾病的不同方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5377/11005305/28a674202fba/10.1177_17407745231206261-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5377/11005305/28a674202fba/10.1177_17407745231206261-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5377/11005305/28a674202fba/10.1177_17407745231206261-fig1.jpg

相似文献

[1]
When should factorial designs be used for late-phase randomised controlled trials?

Clin Trials. 2024-4

[2]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[3]
The future of Cochrane Neonatal.

Early Hum Dev. 2020-11

[4]
The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.

Trials. 2021-9-6

[5]
Design, analysis and presentation of factorial randomised controlled trials.

BMC Med Res Methodol. 2003-11-24

[6]
Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.

Crit Rev Food Sci Nutr. 2010

[7]
Undertaking Studies Within A Trial to evaluate recruitment and retention strategies for randomised controlled trials: lessons learnt from the PROMETHEUS research programme.

Health Technol Assess. 2024-1

[8]
Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on people with long-term respiratory conditions.

Cochrane Database Syst Rev. 2021-8-9

[9]
An examination of effect estimation in factorial and standardly-tailored designs.

Clin Trials. 2008

[10]
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.

Trials. 2020-10-28

引用本文的文献

[1]
Guidance for protocol content and reporting of factorial randomised trials: explanation and elaboration of the CONSORT 2010 and SPIRIT 2013 extensions.

BMJ. 2025-2-4

本文引用的文献

[1]
Estimands for factorial trials.

Stat Med. 2022-9-30

[2]
The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe.

Clin Infect Dis. 2022-11-30

[3]
Combining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficiently.

Clin Trials. 2022-8

[4]
Orthogonal array composite designs for drug combination experiments with applications for tuberculosis.

Stat Med. 2022-7-30

[5]
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).

J Clin Oncol. 2022-8-1

[6]
Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: Clear guidance is needed.

Contemp Clin Trials. 2022-2

[7]
Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.

JAMA. 2021-11-2

[8]
Joint testing of overall and simple effects for the two-by-two factorial trial design.

Clin Trials. 2021-10

[9]
When and how to use factorial design in nursing research.

Nurse Res. 2021-3-11

[10]
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.

Trials. 2020-5-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索